Hepatitis Delta Virus among Mongolians to be decreased
The President of Mongolia, Mr. Battulga received representatives of U.S. based Eiger BioPharmaceuticals, Inc.
The President of Mongolia, Mr. Battulga received representatives of U.S. based Eiger BioPharmaceuticals, Inc. The Eiger BioPharmaceuticals is implementing the Phase 3 of its lead program which focuses on developing a treatment for the Hepatitis Delta Virus infection in Mongolia. The company has been working with Mongolian doctors, especially the Onom Foundation which is committed to liver diseases, for the last 11 years. The company representatives spoke about this cooperation with the President, while exchanging views on the necessity to introduce the treatment of HDV infection and the situation surrounding liver diseases. The President and CEO of Eiger BioPharmaceuticals, Inc, Mr. Cory noted the importance of conducting research and creating the conditions for introduction of the treatment of HDV infection in Mongolia, as well as preventing the infection, and requested attention on this matter on all levels. President Battulga discussed the matter of affordability of the treatment and expressed his commitment to reducing the high prevalence of liver cirrhosis and cancer deaths in Mongolia.